OraSure Technologies (NASDAQ:OSUR) Lowered to “Hold” at StockNews.com

StockNews.com cut shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research note released on Tuesday.

Separately, Evercore ISI lowered their price target on OraSure Technologies from $7.00 to $6.50 and set an in-line rating on the stock in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $6.38.

OraSure Technologies Trading Up 1.1 %

NASDAQ OSUR opened at $5.32 on Tuesday. The firm has a market capitalization of $407.03 million, a P/E ratio of 7.39 and a beta of 0.15. The business has a fifty day simple moving average of $6.33 and a 200 day simple moving average of $6.79. OraSure Technologies has a 12 month low of $4.38 and a 12 month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. The firm had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business’s revenue for the quarter was down 38.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. As a group, sell-side analysts predict that OraSure Technologies will post -0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On OraSure Technologies

A number of large investors have recently modified their holdings of OSUR. AJOVista LLC purchased a new position in shares of OraSure Technologies during the 4th quarter valued at about $39,000. Tocqueville Asset Management L.P. purchased a new position in shares of OraSure Technologies during the 3rd quarter valued at about $75,000. Pathstone Family Office LLC purchased a new position in shares of OraSure Technologies during the 3rd quarter valued at about $80,000. Dynamic Technology Lab Private Ltd bought a new position in OraSure Technologies during the 4th quarter worth approximately $113,000. Finally, Baader Bank Aktiengesellschaft bought a new position in OraSure Technologies during the 4th quarter worth approximately $115,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.